We are live on
!
Find out more
PA
Perceptive Advisors Portfolio holdings
AUM
$6.66B
1-Year Est. Return
360.84%
This Fund
S&P 500
This Quarter
Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
(+29%)
Cap. Flow
+$32.2M
Cap. Flow
% of AUM
1.94%
Top 10 Holdings %
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38
Avg Time Held Equity + Options
2.1
quarters
Top 10 Avg Time Held Equity + Options
2.8
quarters
Top 20 Avg Time Held Equity + Options
3
quarters
Avg Time Held Equity only
2.2
quarters
Top 10 Avg Time Held Equity only
2.9
quarters
Top 20 Avg Time Held Equity only
3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RXDX
Ignyta, Inc.
RXDX
|
+$23.8M |
| 2 |
Viatris
VTRS
|
+$14.8M |
| 3 |
Eagle Pharmaceuticals, Inc.
EGRX
|
+$14.4M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$12.4M |
| 5 |
NEVRO CORP.
NVRO
|
+$12.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$19.4M |
| 2 |
bluebird bio
BLUE
|
+$16.3M |
| 3 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
+$12.1M |
| 4 |
uniQure
QURE
|
+$11.1M |
| 5 |
RLYP
RELYPSA INC COM
RLYP
|
+$10.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.96% |
| 2 | Miscellaneous | 17.3% |
| 3 | Consumer Staples | 0.52% |
| 4 | Financials | 0.09% |
| 5 | Technology | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
126
CONMED
CNMD
$1.36B
| $498K | 0.03% |
+8,554
| New | +$461K |
2015 Q2
0 quarters
|
|
127
Tenet Healthcare
THC
$21.5B
| $492K | 0.03% |
8,500
| – | – |
2014 Q3
3 quarters
|
|
128
Apyx Medical
APYX
$110M
| $482K | 0.03% |
172,700
-27,300
| -14% | -$75.1K |
2015 Q1
1 quarter
|
|
|
INFI
129
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $449K | 0.03% |
41,000
-20,000
| -33% | -$257K |
2014 Q4
2 quarters
|
|
|
JNP
130
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
| $411K | 0.02% |
+44,900
| New | +$339K |
2015 Q2
0 quarters
|
|
|
AKAO
131
DELISTED
Achaogen Inc
AKAO
| $362K | 0.02% |
60,000
| – | – |
2014 Q1
5 quarters
|
|
|
OREX
132
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $350K | 0.02% |
+7,060
| New | +$422K |
2015 Q2
0 quarters
|
|
|
KERX
133
DELISTED
Keryx Biopharmaceuticals Inc
KERX
| $343K | 0.02% |
34,380
-50,000
| -59% | -$536K |
2015 Q1
1 quarter
|
|
|
PARN
134
DELISTED
Parnell Pharmaceuticals Holdings Ltd
PARN
| $341K | 0.02% |
68,800
-127,700
| -65% | -$563K |
2014 Q3
3 quarters
|
|
135
Supernus Pharmaceuticals
SUPN
$2.45B
| $331K | 0.02% |
+19,470
| New | +$277K |
2015 Q2
0 quarters
|
|
|
CBM
136
DELISTED
Cambrex Corporation
CBM
| $322K | 0.02% |
7,331
| – | – |
2014 Q4
2 quarters
|
|
|
XENT
137
DELISTED
Intersect ENT, Inc
XENT
| $293K | 0.02% |
+10,251
| New | +$269K |
2015 Q2
0 quarters
|
|
|
SYNH
138
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $291K | 0.02% |
+7,261
| New | +$251K |
2015 Q2
0 quarters
|
|
139
Gilead Sciences
GILD
$183B
| $288K | 0.02% |
2,457
-7,543
| -75% | -$824K |
2015 Q1
1 quarter
|
|
|
GTS
140
DELISTED
Triple-S Management Corporation
GTS
| $272K | 0.02% |
11,147
| – | – |
2014 Q2
4 quarters
|
|
141
Universal Health Services
UHS
$10.6B
| $268K | 0.02% |
1,883
-350
| -16% | -$43.8K |
2014 Q2
4 quarters
|
|
142
Phibro Animal Health
PAHC
$1.49B
| $265K | 0.02% |
6,809
| – | – |
2014 Q4
2 quarters
|
|
|
MRGE
143
DELISTED
MERGE HEALTHCARE INC COM STK (WI)
MRGE
| $264K | 0.02% |
55,015
-27,412
| -33% | -$131K |
2014 Q2
4 quarters
|
|
144
Community Health Systems
CYH
$422M
| $250K | 0.02% |
+4,813
| New | +$216K |
2015 Q2
0 quarters
|
|
|
HNT
145
DELISTED
HEALTH NET INC
HNT
| $246K | 0.01% |
3,831
-278
| -7% | -$16.6K |
2014 Q4
2 quarters
|
|
146
LeMaitre Vascular
LMAT
$1.86B
| $239K | 0.01% |
+19,838
| New | +$195K |
2015 Q2
0 quarters
|
|
147
Integer Holdings
ITGR
$4.3B
| $237K | 0.01% |
4,817
| – | – |
2015 Q1
1 quarter
|
|
148
Elevance Health
ELV
$92.2B
| $236K | 0.01% |
+1,436
| New | +$229K |
2015 Q2
0 quarters
|
|
149
McKesson
MCK
$112B
| $228K | 0.01% |
1,015
| – | – |
2015 Q1
1 quarter
|
|
|
LHCG
150
DELISTED
LHC Group LLC
LHCG
| $226K | 0.01% |
5,917
| – | – |
2014 Q4
2 quarters
|
|
Similar funds
QP
FCBT
RWM
AWA
WHRC
KGA
LSERS
CAG
Perceptive Advisors's Q2 2015 Portfolio in Review
As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Perceptive Advisors's Q2 2015 filing shows 55 new, 41 increased, 36 reduced and 38 closed positions. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M. The largest sale was Neurocrine Biosciences, an estimated $19.4M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Miscellaneous and Consumer Staples.
- Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
- Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
- Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
- Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
- Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
- Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
- Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.
Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.